Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2011 financial results on Tuesday, July 26, 2011 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, July 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the second quarter, as well as current corporate developments.
View dataConference call details:
Date: Tuesday, July 26, 2011
Time: 4:30 p.m. ET
Dial-in (U.S.): 877-941-8609
Dial-in (International): 480-629-9818
Web cast: www.questcor.com
To access an audio replay of the call:
Replay (U.S.): 800-406-7325
Replay (International): 303-590-3030
Replay Passcode: 4455547
Conference call details: Date: Tuesday, July 26, 2011 Time: 4:30 p.m. ET Dial-in (U.S.): 877-941-8609 Dial-in (International): 480-629-9818 Web cast: www.questcor.com To access an audio replay of the call: Replay (U.S.): 800-406-7325 Replay (International): 303-590-3030 Replay Passcode: 4455547
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com. |
